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With an escalating incidence of breast cancer cases all over the world and the deleterious psychological
impact that mastectomy has on patients along with several limitations of the currently applied modali-
ties, it’s plausible to seek unconventional approaches to encounter such a burgeoning issue. Breast tissue
engineering may allow that chance via providing more personalized solutions which are able to regen-
erate, mimicking natural tissues also facing the witnessed limitations. This review is dedicated to explore
the utilization of adipose tissue-derived mesenchymal stem cells for breast tissue regeneration among
postmastectomy cases focusing on biomaterials and cellular aspects in terms of harvesting, isolation, dif-
ferentiation and new tissue formation as well as scaffolds types, properties, material–host interaction and
an in vitro breast tissue modeling.
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Breast cancer is the commonest malignant disease and the fifth commonest cause of death among females worldwide
with nearly 1.5 million new cases diagnosed each year (1.7 million new cases in 2012) [1,2]. Thus, it represents about
12% of all new cancer patients and 25% of all malignant diseases in females [2]. In England, approximately 46,000
new cases are annually diagnosed with nearly 40% undergo mastectomy [3]. The risk of breast malignancy doubles
each decade until reaching the menopausal period, after which there is a slower risk increment. Nevertheless, it is
commoner in the postmenopausal period [2].
The National Institute for Health and Clinical Excellence (NICE) guidelines recommended the immediate
breast reconstruction (IBR) for all patients undergoing mastectomy, however, significant comorbidities or the use of
adjuvant therapy may rule out this option [4]. In fact, only 21% undergo IBR at their initial operation [5]. Mastectomy
represents a life-altering morbidity with physical and psychological impacts that necessitates a multidisciplinary
management [5]. Additionally, patients usually suffer from significant anxiety, depression, insomnia, suicidal ideas
and feeling of shame [6]. Therefore, breast reconstruction relieves the sense and fear of disfigurement and improves
the emotional and sexual well-being [5,7]. Those reasons, along with the limited breast-preserving surgery modalities,
have led to a special motivation in the field of breast tissue engineering [6], as personalized treatments have a pivotal
role in enhancing life quality and expectancy [8].
The incorporation of tissue engineering and stem cells revolutionizes the field of tissue regeneration [9], as this
provides custom-designed solutions for tissue reconstruction and offers like-for-like tissue replacement without
the adverse effects of immunosuppression or donor-site morbidity [10]. Adipose tissue-derived mesenchymal stem
cells (ADSCs) are multipotent mesenchymal stem cells (MSCs) with similar features to bone marrow-derived
MSCs (BMSCs) [11] (Figure 1). These cells are considered ideal for adipose tissue regeneration, as they proliferate
and mature into adipocytes to restore or augment the lost volume [12], besides secreting essential growth factors
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Figure 1. Advantages of adipose tissue-derived











Figure 2. Anatomy of adult female
breast. The major breast structures
are the nipple–areola complex, the
large ductal system and the terminal
duct lobular units.
(i.e. VEGF) for angiogenesis and adipogenesis [9]. This explains the crucial role of ADSCs in maintaining regenerated
tissue volume [5].
Breast anatomy, histology & development
The breast is a complex dynamic organ, consists of various cell types that are actively interacting under the control of
microenvironmental signals throughout the process of maturation [13]. The developmental stages are characterized
by radical compositional, architectural and functional changes which are mediated by significant alterations in
gene expression [14]. Anatomically, the breast consists of 15–20 lobes and each lobe consists of 20–40 lobules
that are connected by ducts and comprise the mammary glands [6] (Figure 2). It is highly vascular and contains a
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Figure 4. The normal and malignant breast histology. Hematoxylin and eosin staining of normal adult breast
tissue [127]. The normal gland is a well-organized structure. The breast acini and ducts consist of a central lumen and
are lined by polarized luminal epithelial cells (inner layer) and myoepithelial cells (outer layer). A basement
membrane separates these two layers from the surrounding stroma and is composed of stromal extracellular matrix
and stromal cells (i.e., fibroblasts and adipocytes). Basement membrane contains different types of proteins (mainly
collagen type IV and laminin).
Reproduced from [19] with permission from Elsevier, copyright 2008 [18].
large number of lymphatic vessels and lymph nodes, which drain into the axillary and internal mammary lymph
nodes [6,7,14]. A loose connective tissue layer allows the free movement of the breast over the deep fascia [7], while the
suspensory ligament (Cooper’s ligament) attaches the breast to the overlying skin and the underlying structures [15].
The size and weight of the breast differ significantly among individuals ranging from small-medium sized breasts
(≤500 g) to large sized breasts (750–1000 g) [16].
Histologically, this specialized organ follows ‘the rule of two’ by being composed of two types of epithelial cells,
stroma and main structures [17] (Figures 3 & 4). It encompasses glandular, ductal, connective and adipose tissues
with numerous cell types, such as preadipocytes, adipocytes, epithelial cells, endothelial cells, MSCs, fibroblasts,
myofibroblasts and leukocytes [18]. During puberty, the growth and development of the breast are governed locally
by the paracrine reciprocal interactions between ductal epithelial cells and stroma, and systemically by the hormones
produced by the pituitary gland and ovaries (i.e., estrogen and growth hormone are essential for mammary ductal
morphogenesis) [13].
While during and after menopause, decreased levels of estrogen and progesterone caused by declining ovarian
function leads to postmenopausal breast involution [14]. Consequently, breast lobules diminish in number and
shrink in size resulting in a lower breast density [6].
Epithelial cells interactions with extracellular matrix proteins
Epithelial cells survival, proliferation, differentiation, polarity and invasive capacity are governed by cell–cell and
cell–microenvironment interactions [18]. The cell–extracellular matrix (ECM) attachment has a critical role in
epithelial differentiation, polarity and organization, as this is achieved when cell integrins bind to ECM collagen,
laminin and fibronectin (i.e., α2β1 integrins bind to collagen and laminin) [18–20]. For instance, in nonmalignant and
malignant epithelial structures, ligation of β4 integrin (which is induced via the interaction with laminin) regulates
polarity and enhances cellular resistance to apoptosis regardless of the growth status [21]. That’s why apoptosis of
the mammary epithelial cells ensues when stimuli from integrin-ECM adhesion are absent [22].
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Table 1. Factors controlling breast tissue properties.
Factor(s) Parameter(s) Ref.
The ratio of adipose to fibrous tissues Density [6]
The breast skin envelope and adipose tissue Size and shape [7]
The adipose tissue clusters and lobules that are distributed between fibrous and glandular tissues Consistency, bulk and contour [6,7]
Cooper’s ligaments Support, shape and contour [15]
The glandular epithelium and ductal structures Density and consistency [6]
ECM remodeling is considered a prerequisite for acini formation, which is achieved by the activity of matrix
metalloproteinases enzymes (MMPs) (i.e., MMP14, MMP13, MMP2 and MMP9) [23]. Moreover, the mechanical
characteristics of the ECM govern the formation and organization of the polarized growth-arrested structures, as
increased ECM density and stiffness disrupts the polarized organization of the acinar and ductal structures formed
by epithelial cells [23,24].
Biomechanical properties of breast tissue
Generally, the mechanical properties of the soft tissues involve a sophisticated combination of elasticity and viscosity
that governs tissue deformation [15]. Breast viscoelasticity is governed by woman’s age, hormonal levels, pregnancy,
lactation, menstrual cycle and tumors formation [25]. Table 1 illustrates the role of different breast tissue components
in controlling breast tissue properties. For normal breast, the elastic modulus (Young’s modulus) of the fatty tissues
is 3–20 kPa and for the fibroglandular tissues is 3–44 kPa [18]. These results were obtained using indentation or
compressive force sonography, sonoelastography and magnetic resonance elastography [18].
Furthermore, the breast tissue is characterized by a tensile response that reveals a nonlinear stiffening at high
deformation [15]. Malignant and benign breast tumors, when compared with normal breast tissue, are generally
stiffer and exhibit a higher nonlinear increment in stiffness because they undergo collagen remodeling [15].
It is worth noting that the static and dynamic body forces applied to the breast are supported mainly by three
structures: Cooper’s ligaments, pectoralis fascia and the rib cage, which support tension loads, shear forces at breast
base and compression loads, respectively [16].
Current clinical practices for breast reconstruction
Several factors should be considered when deciding the treatment approach for breast cancer, such as tumor stage
and size, patient’s general health status and comorbidities [6]. Surgical resection comprises two standard procedures,
mastectomy and lumpectomy, which are selected according to breast tumor progression [6].
There are two factors determining the type and timing of the reconstructive procedure, patient’s general health
status and then patient’s preference [6]. IBR following mastectomy has crucial advantages, which are: single operation,
shorter hospitalization and better psychological and aesthetic outcomes [26]. However, all breast augmentation and
reconstruction should be weighted for benefits and risks, as all patients have different requirements and some
procedures may be suitable for some where others are not [27].
Implant-based reconstruction
Breast implant is a simpler procedure with shorter operation time [28]. It is either performed as a two-stage procedure
that involves implantation of a tissue expander followed by replacement with a fixed-volume permanent implant,
or a single-stage fixed-volume permanent implant [29]. Many women commonly choose silicone as their option for
implants, but saline is another option less popularly chosen, as women prefer the lower expenses and feel of the
silicone implants, despite the complications possible [30].
This procedure is associated with several complications that may lead to implant failure (Table 2), as the reported
incidence of implant removal is 20% within 8–10 years [31], with complication probability increasing drastically in
patients with high-stage breast cancer undertaking radiation therapy [32].
Autologous flap reconstruction
Breast reconstruction using autologous tissues offers more durable results, greater consistency, better aesthetic out-
come and better tolerance to radiotherapy and obviates the complications associated with implants [26]. Autologous
flap reconstruction involves the removal of healthy tissue from a location of the patient’s body, to be relocated to
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Table 2. Complications associated with implant-based reconstruction.
Complication Description Ref.
Short-term complications Hematoma, seroma [28]
Infection: may lead to intractable cellulitis and subsequent implant removal [31]
Mastectomy skin flap necrosis [28]
Long-term complications Pain in the local surgery area [77]
Breasts’ asymmetry [32]
Loss of nipple sensation [7]
Implant wrinkling or ripple formation [32]
Implant malposition, displacement or deformation [18,32]
Silicone or saline leakage [7]
Implant deflation, rupture or extrusion [18,28]
Capsular contracture: due to foreign body reaction [7]
Post-radiotherapy complications: as high as 60% with an increased risk of implant extrusion and capsular contracture [31]
Scar tissue formation [77]
Table 3. Autologous flaps for postmastectomy breast reconstruction.
Classification Type
Pedicled flaps Latissimus dorsi flap
Pedicled Transverse rectus abdominis musculocutaneous flap
Free flaps Free Transverse rectus abdominis musculocutaneous flap
Deep inferior epigastric artery flap
Superficial inferior epigastric artery flap
Superior gluteal artery perforator flap
Inferior gluteal artery perforator flap
Transverse musculocutaneous gracilis flap
Reproduced from [35].
the breast, this has been used effectively to create a natural feeling breast and hence works towards increasing the
confidence of the patient [30]. However, these procedures are more complex with longer recovery and are associated
with potential donor and recipient-site morbidity [28]. Consideration of donor-site tissue collection is vital, as
removing tissue from some sites could result in the formation of hernias [33], for example removing flap-tissue from
the lattisumus dorsi could result in a lumbar hernia because of the reduced layers of tissue, requiring further surgery
to insert a mesh to keep the hernia from rupturing [34].
According to their relation to the donor-site, tissue flaps can be classified into two main categories: pedicled flaps
and free flaps [35] (Table 3). Pedicled flaps is tissue which have the blood vessels joined to in an intact form, whereas
free flaps on the other hand have to be connected to the blood supply of the breast due to complete flap removal
from the donor site [30].
Free flaps are carried out more successfully, sourcing the donor sites from adipose rich areas, such as the abdomen
flaps to be moved to the breast area, the tissue having a higher chance of survival with less likely reduction in
strength at the donor-site [33].
Cellular breast restoration
This approach can be achieved through autologous lipotransfer or adipose tissue engineering (Table 4).
Adipose tissue-derived stem cells
Adipose tissue is normally found under the skin and consists of fat cells (adipose cells or adipocytes) which are
specialized in the production and maintenance of large fat globules. Adipose tissue is an abundant, accessible and
replenishable source of adult somatic stem cells. ADSCs prevent severe graft-versus-host disease in vitro and in
vivo and to be genetically stable in long-term culture and therefore they have great potential applications for the
repair and regeneration of acutely and chronically damaged tissues [36]. MSCs were named over 25 years ago to
represent a class of cells that can be isolated from many adult tissues such as bone marrow, adipose tissue, cord
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Table 4. Different approaches for cellular breast restoration.
Procedure Description Ref.
Autologous lipotransfer It involves harvesting and relocating adipose tissue to reconstruct the breast without using a
scaffold and is considered as a limitless source for reconstructing soft tissues.
Advantages:
- Inexpensive procedure.
- Less invasive than flap or implantation surgeries, involving less risks.
- Breast size and shape is restored to appear and feel more natural.
- Enhanced engraftment, volume retention and long-term survival with improved healing,
angiogenesis and collagen synthesis (by the effect of ADSCs growth factors: TGF-1, IGF and
VEGF).
Limitations:
- Poor clinical results, as it is associated with 50–70% fat graft resorption, which can be
attributed to poor revascularization.
- The harvested adipocytes cannot proliferate because they are mature and terminally
differentiated.
- Formation microdeposits of serum calcium that interfere with radiological tumor diagnosis.
Cell-assisted lipotransfer:





It involves recruitment of resident surrounding preadipocytes by changing the tissue




It encompasses isolation and culturing of preadipocytes and capillary endothelial cells. These cells
are then seeded in a biodegradable polymeric scaffold supplemented with suitable angiogenic
and adipogenic growth factors, to be transferred to tissue sites.
[37]
ADSC: Adipose tissue-derived stem cell.
and peripheral blood, fallopian tube, fetal liver and lung. MSCs can be defined as plastic-adherent cells that have a
multipotent differentiation capacity in vitro and can differentiate into osteocytes (bone), chondrocytes (cartilage)
and adipocytes (fat) cells [37] (Figure 5).
MSCs can also be defined to have a fibroblast-like morphology as well as being able to form collonies in
vitro. They can directly differentiate into mesodermal lineages and also have the ability to transdifferentiate into
ectoderm and endoderm lineages [38]. ADSCs gained a lot of interest over the past years for their unique multi-
lineage differentiation potential and immunomodulatory properties, hence, used for many different applications.
They are being viewed from a traditional cell therapy perception as well as contributing to a new tissue formation
through terminal differentiation or modulation of endogenous repair processes as they home to sites of injury
and/or of inflammatory responses via paracrine signaling [39].
ADSCs modulate the immune system by applying regulatory effects on various immune cells and can modulate
many T-cell functions including cell activation. They have the ability to secrete anti-inflammatory cytokines,
expand regulatory T cells and improve the outcome of allogeneic transplantation via promoting hematopoietic
engraftment [40].
In particular, the ADSCs are a highly promising cell type for clinical applications due to its ease of isolation
from an abundant source [40]. However, stem cell implantation into the breast should be done so cautiously, as
Donnenberg et al. have shown that ADSCs can accelerate the growth of breast cancer cells, therefore the patient
should be free of all cancer and passed cancer remission before ADSCs tissue engineering procedures begin [41].
Isolation & culture
ADSCs can be isolated by a variety of techniques, grown and expanded using numerous reagents and differentiated
in a range of media, proteins and small molecules (Figure 6). Bone marrow has been commonly considered as the
main source to isolate MSCs, but it has some considerable negative issues for the patient and also some disadvantages
compared with other tissue types. However, harvesting ADSCs have shown promising benefits attributed to the
abundance of adipose tissues and therefore they can be collected in higher numbers as well as from different
locations of the body [42].
In general, there are two techniques for harvesting adipose tissue; liposuction and resection or needle biopsy
where the tissue is first washed with phosphate-buffered saline to remove any debris, then placed on culture plates in
a sterile condition to digest the tissue by chopping the fatty tissue into fine pieces and incubated while in collagenase
then centrifuged to separate the mature adipocytes that are floating and to remove the non-adherent cells. The
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Figure 5. Culture conditions for the differentiation of mesenchymal stromal cells.
Reproduced from [74] with permission from Elsevier, copyright 2008 [74].



















Figure 6. Scheme for processing of adipose tissue and isolation of adipose tissue-derived stem cells.
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cultured cells are then recultured for 3–4 weeks while being passaged to proliferate and expand in culture followed
by cryopreservation and controlled freezing and finally long-term freezing storage [42].
Growth & differentiation
ADSCs are self-renewing cells that can be used clinically to replace or repair damaged tissues. Currently, it is
clear that the clinical promise of ADSCs is supported by their attractiveness associated with self-renewal and
pluripotency to commit, differentiate, and mature into specific phenotypes under the control of cell-intrinsic
signaling mechanisms [43]. The process of ADSCs differentiation can be achieved by the use of transcription factors
such as adipocyte determination and differentiation factor 1 and adipocyte-specific transcription factors (C/EBPα)
under specific micro-environmental conditions [43].
Adipogenesis
ADSCs have the capability to differentiate into a number of cell types including adipocytes, osteocytes and chon-
drocytes. The adipocytes phenotype is characterized by intracellular accumulation of lipid droplets as well as
transcription of adipocyte-specific genes. ADSCs differentiate to form adipocytes, the cells responsible for the
synthesis and storage of fat or could also be named as generation of lipid-droplet bearing adipocytes. Differ-
entiation markers of adipogenesis are important for the identification and isolation of differentiated adipocytes.
Adipogenesis is a process whereby ADSCs or preadipocytes differentiate to acquire phenotypic characteristics of
mature adipocytes [43]. Adipogenesis is induced in the presence of isobutyl-methyl-xanthine which can involve in
phosphodiesterase inhibition, followed by PKA activation, and ultimately, leads to the activation of C/EBPα [43].
Adipogenic differentiation & epigenetics
Epigenetic refers to heritable changes involving the gene expression without any changes in the DNA sequences.
The interaction between transcription factors and genes are modulated by DNA methylation which regulates the
gene expression by modifying the chromatin or nuclear architecture. As mentioned above, adipogenesis is a highly
regulated process that involves several transcription factors and researches have shown that DNA Methylation as
well as other factors is responsible for the regulation of adipogenic differentiation [44].
Enhancing the differentiation
Adipogenic differentiation can be induced using a culture medium containing isobutyl-methyl-xanthine, in-
domethacin and dexamethasone until mature adipocytes are obtained (after 12–14 days). The cells are then fixed
by formalin solution and ethanol and air dried before dye staining. It is possible to tune or control the amount
of differentiation by either addition of more adipogenic differentiation media, addition of rabbit serum (which
induces adipocyte-like differentiation) or using different PPAR-γ agonists [45].
Cell surface marker expression
According to the International Society for Cellular Therapy standard criteria, expression of specific set of cell
surface markers is one of the essential ADSCs’ characteristics. ADSCs constitute a heterogeneous population of
cells in terms of their morphology and expression of surface antigens and this is the reason why there hasn’t been an
identified specific surface marker for the ADSCs [46]. The cells which show a positive expression for CD29, CD44,
CD73, D90, CD105 and negative expression of CD14, CD34, CD45 and HLA-DR are considered as MSCs [46].
Growth factors
ADSCs can be influenced by different growth factor receptors that have been identified on their surface. Growth
factor receptors such as: EGFR, bFGFR, IGFR, DGFR, TGFRI and RII have been reported to be important for
MSCs self-renewal and differentiation [47].
Challenges facing adipose tissue engineering for breast regeneration
Cell survival & vascularization
Ensuring adequate nutrition and oxygenation have been recognized as a critical challenge in tissue engineering field
in general and breast tissue engineering in particular attributed to the fact that the higher the volume/surface ratio
the heavier the demand of adequate vascular supply [48]. Hence, vascularization remains as a major stumbling block
in the way of ensuring long-term survival of the engineered tissue and an enhanced tissue configuration to emulate
the 3D structure of the removed breast [48].
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Better understanding of the close correlation between adipose and vascular tissue is a key to achieve the desired
clinical translation of adipose tissue engineering. It is crucial to note that angiogenesis process occurs before the
adipogenesis based on findings during embryological development, wound healing as well as experimentally [7]. The
accumulation of fat after involution of a capillary hemangioma and the presence of adipose cells after the foundation
of vascular connections act as vivid examples. However, there is no direct conjunction between endothelial cells
and preadipocytes as cellular interactions are fostered via secreted or matrix-bound factors instead [7]. The action of
such factors, which are produced by microvascular endothelial cells, was demonstrated to promote the proliferation
and differentiation of pre-adipocyte during adipogenesis [49]. Furthermore, it has been shown that the adult adipose
tissue tends to secrete growth factors and hormones which believed to be proangiogenic, in turn [50,51]. Thus, it is
essential to consider the intimate relationship between both processes while shaping the way towards adipose tissue
engineering.
Findlay et al. carried out a study, in order to increase the volume of vascularized adipose tissue that could be
produced, reaching for a solution to increase the amount of breast tissue that can be reconstructed [52]. To test their
theory, they created chambers subcutaneously within pig superficial circumflex pedicle, inserting free fat grafts, poly
(L-lactide-co-glycolide) sponge, muscle and vascular pedicle or leaving the vascular pedicle by itself [52]. Findlay
et al. found that all the chambers within 6 weeks, had suffused with new tissue, which was also sufficiently supplied
with blood from the arteriovenous pedicle [52]. This indicating that adipose tissue can be sufficiently scaled to fill a
wanted cavity, and if located near or attached to a pedicle can become vascularized. Yuan and Ogawa have shown
that mechanical forces can be detrimental to the growth of adipose cells, as opposed to musculoskeletal tissue
that seems to be encourages by mechanical forces [53]. Indicating that Findlay et al.’s study could have obtained
its success, by limiting the mechanical stresses exhibited to the chambers produced in the superficial circumflex
pedicle [53].
On the other hand, adipose tissue is highly vascularized, with a two- to three-times resting blood flow rate more
than that of skeletal muscles and the existence of such an extensive vascular network guarantees the delivery of
nutrients via simple diffusion [6]. Yet, it is limited within an approximately 150 μm in vivo distance which means
that the metabolically active cells beyond that distance are prone to hypoxia unless we can warrant a well-established
vascular network in the engineered tissue mimics that of the natural organ to ensure application of adipose tissue
engineering practice [6]. Many approaches have been pursued to promote vascularization and angiogenesis, albeit
unfettered of limitations, see Table 5.
Volume–skin coverage coordination
There is no one-size-fits-all approach in breast restoration procedures as those have to be considered in a case-by-
case manner regardless the used materials whether implant-based, autologous, or engineered tissue components.
For better aesthetic results, the required volume for restoring breast mound has to be known before undergoing
reconstructive surgery and this practice is still challenging as it is surgeon-reliant and often require a high degree of
experience [7]. However, utilizing tissue engineering modalities allow an opportunity of predetermining the desired
shape and size of the restored breast by determining the scaffold shape and cell numbers, for instance, especially if
3D imaging techniques are embraced to produce patient-specific breast models. Nevertheless, further adjustments
have to be included to advance the level of personalization [7].
Large animal model
Small animal models are frequently employed to test the practical implication of adipose tissue engineering and
its workability. However, it is preposterous to use similar species when considering mammary tissues, hence, larger
animal models should be utilized but how similar the outcome to the humans would be questionable here [6]. The
anatomy, histology and hormonal susceptibility of large animal models are quite relevant to that of humans along
with providing an adequate area to contain large size implants [6,54]. Many factors have to be considered while
evaluating the right animal model for a particular study as animals required to test large subcutaneous constructs
should have similar skin and subcutaneous tissues to that of human, for instance [6]. Additionally, blood vessels
must have a satisfactory caliber to allow anastomosis for microsurgery maneuvers, a suitable tissue structure is
required to permit attaining, isolation and culturing of pre-adipocytes. The size of animal must be large enough
to effectively demonstrate convection and diffusion-dependent transport with a reasonable gross morphology to
insert the construct without affecting the animal’s ability to move or its lifestyle. Growth rate and lifespan has to be
borne in mind also, as a rapid weight gain may deter the ability to monitor the implant and a shorter life expectancy
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Table 5. Biomaterial-derived scaffolds investigated for adipose and/or breast tissue regeneration.
Type of scaffold Type of material Ref.




































Natural scaffolds‡ 1. Adipose-derived ECM
2. Collagen


















Biological scaffolds Decellularized matrix [5,28,37,42,45]
Injectable scaffolds Alginate / o-carboxymethyl chitosan
Polylactic-co-glycolic acid / hydrogel
Alginate / polyvinyl alcohol with the inclusion of fibrin nanoparticles
Alginate / collagen
Natural scaffolds: alginate, chitosan, hyaluronic acid, collagen, decellularized adipose
tissue and small intestinal submucosa








Therapeutic scaffolds§ Collagen / chitosan / glycosaminoglycan [6]
Combination scaffolds 1. Injectable composite: beads in a delivery gel
2. Gelatin sponges / Polyglycolide mesh / monofilament polypropylene mesh
3. Polylactic-co-glycolic acid / polylactic acid










†Synthetic scaffolds are easier to fabricate, allow tailoring of the chemical, mechanical (strength and stiffness) and biodegradation properties, permit easier addition of ECM
components and growth factors and have higher uniformity and compatible mechanical and thermal characteristics with biological tissues [18,28,60,128]. Limitations: they
are generally less biocompatible and may generate immunological responses and cellular toxicity [18].
‡Natural scaffolds are more biocompatible and mimic native ECM (i.e. they provide cellular receptor-binding ligands and undergo cell-induced proteolytic degradation
and remodeling) [18,28,60,128]. Limitations: they require complicated purification process, have poor mechanical, thermal and biodegradation characteristics, may initiate
strong immunological responses and may transmit diseases [18].
§Therapeutic scaffolds involve an incorporated therapeutic agent (i.e., a drug or a growth factor) [6].
ECM: Extracellular matrix.
would definitely interfere with long-term studies [7]. It is has been observed by researchers and investigators at the
University of Texas M.D. Anderson Cancer Center that Yucatan Micro Pigs can be considered as a model animal
since they adhere to almost all criteria explained above. Moreover, they are hairless, pliable with a suitable size and
a defined growth rate which add extra virtues for them to be utilized [54,55]. However, further characterizations are
crucial to reach out the ultimate decision regarding the model animal nomination.
Potential risk of neoplastic behavior
Oncological safety is often questioned when it comes to utilizing ADSCs for breast restorative techniques and that
is because tumor cells are usually following similar pathways to those applied during tissue engineering process
(i.e., proliferation, neovascularization and matrix turnover) which may herald neoplastic transformation especially
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in post-malignancy situations [48]. Few in vitro studies betrayed the implication of MSCs in oncological risk
potentials [56,57]. However, nothing is proved on clinical context yet [57,58]. Affirming stem cells safety in breast
tissue regeneration necessitates more comprehensive and controlled clinical trials [59].
Macro-environment consideration: mechanical & structural challenges
There are certain criteria for the designed scaffolds that need to be fulfilled before being considered for breast tissue
engineering. Matching the shape of the removed tissue along with providing the essential mechanical support to
prevent collapse during the early stage of implantation are one of them and the latter has to be precisely balanced
with the rate of degradation [48]. While a complete degradation of the implanted scaffolds accompanied by de
novo soft tissue generation is a paramount for breast tissue engineering, it is fundamental to optimize that rate
in a manner which ensures adequate maintenance of the spatial structure for the restored volume. Furthermore,
it is worthy to monitor the by-products resulting from degradation to see whether they are safe/harmful to the
surrounding tissues or may curb the process of tissue regeneration [48].
Evidences of soft tissue formation for both synthetic and natural scaffolds have been reported. A collagen scaffold
in particular, has shown a greater cellular attachment and an enhanced lipid accumulation in vitro [60]. Yet it has
disappeared completely after its in vivo implantation within 4 weeks due to its rapid degradation rate which may
have a nondesirable impact on the sustainability of breast contour and the mechanical support. Similar behavior
has been demonstrated for the polylactic acid synthetic scaffolds [61]. In general, it is easier to work with synthetic
scaffolds in terms of sustained control over the material properties [62]. However, natural scaffolds tend to be
superior with respect to host tissue reaction, soft tissue formation and degradation characteristics [60].
As an endeavor to tackle challenges associated with mechanical and structural aspect, Yuksel et al., described a
complex scaffold design dedicated to match the desired criteria for the engineered breast tissue [48]. The concept of
this scaffold is based on a three-layer composition. A thin outer layer, which made of a fibrillar matrix, is designated
to withstand the mechanical stress that may result from a material-tissue mismatch besides enhancing ‘on-the-shelf
availability’ via adaptation to volume variation. The second rigid layer is manufactured from a slowly degrading
polymer such as polylactic-co-glycolic acid will ensure volume maintenance through providing a structural support
which can be further reinforced by a 2–3 mm layer of a honeycomb structure to enhance its strength. This layer
accommodates the central highly porous portion which will boost tissue ingrowth [48].
Micro-environment considerations
Whether synthetic or biological, controlling a scaffold behavior and cell-material interactions is still a real chal-
lenge [63]. Biological materials, including collagen and fibrin matrices are recognized by their rich cell signaling
domains but most of them are uncharacterized resulting in a poorly regulated cell-scaffold communication [48,64].
Synthetic scaffolds, on the other hand, provide the option of more predictable physical and biological cell-material
interactions as well as a better control over structural properties like porosity, density and degradation. However,
they are far from resembling the natural external environment with its essential triggering potentials for tissue
engineering purposes [48,65].
Several attempts of constructing hybrid scaffolds containing both synthetic and natural components were made to
enhance biological interactions such as directing cell migrations and facilitating cell mobility via natural secretion of
proteases [66,67]. Another successful example represents the modification of polyethylene glycol (PEG) acrylates with
either arginine-glycine-aspartic acid peptide (a cell adhesive peptide) or with heparan sulfate (an ECM component)
that were successfully incorporated within scaffolds to promote cellular attachment and allow reservation of
heparan-binding growth factors [48]. Matrix modification/governing chemotactic signals are also play a critical role
in eliciting inward movement of essential cellular components for breast tissue engineering such as pre-adipocytes
and endothelial cells [48]. Such strategies could be embraced for a better control over cell-material interactions.
Cellular exhaustion owing to fibrosis, insufficient blood supply and inappropriate mechanical properties of
scaffolds has been observed to impede cellular migration and inhibit translation of the outcomes for larger defects
in an in vivo study [48]. Such a challenge can be overcome via delivering matrix degradation enzymes such as
plasminogen activator to clear the matrix wall, thence, boosting cellular migration and vascular formation. In theory,
distribution of enzymatic activity could be achieved by creating shells of increasing plasminogen activator levels
superior to its physiological concentration so that, providing the critical gradient to maximize cell migration [48].
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Epithelial–mesenchymal transition
There is increasing research which provide adequate evidence to support the role of epithelial–mesenchymal
transition in different stages of cancer and tumor cell progression, invasion and metastasis [68]. While epithelial–
mesenchymal transition progressing, epithelial cancer cells obtain some molecular changes that facilitate the loss
of epithelial features and obtain mesenchymal phenotype. Such alterations encourage cancer cell migration [68].
Additionally, new evidence suggests that epithelial-mesenchymal transition is associated with the increased enrich-
ment of cancer stem-like cells which exhibit mesenchymal characteristics that are resistant to target therapy and
chemotherapy [68].
Dormant cancer cells
Tumor dormancy is an important part of tumor progression process [69]. While, there is major advances in treatment
of breast cancer, some factors need to be considered such as tumor heterogeneity as well as mechanisms of resistance
which may still affect the standard therapies and make it not effective enough in destroying entire cancer cells, such
as dormant cells [69]. However, the biology of breast cancer recurrence should be investigated further to make sure
adequate prognosis and therapies obtained [69].
Application of ADSCs in tissue engineering
For the past few years, ADSCs used as an important cell source and also known as the gold standard for many
applications in regenerative medicine [70]. In particular, for breast reconstruction became very interested by clinicians
and researchers worldwide because they display great potential for proliferation and differentiation to adipocytes,
and obtain acceptable mature adipose graft volume. There are some applications of ADSCs which have more value
than others and this will be discussed here. For instance, fat grafting and tissue engineered construct are two main
important applications.
Fat grafting
attracted significant attractions for the past few years and particularly for breast reconstruction autologous fat
grafting successfully used by clinicians for various purposes including breast size alteration, filling small-volume
defects post-breast-conserving therapy [71,72] and contour defects in implant-based breast reconstructions [73,74].
Overall outcome so far related to fat grafting represent that the larger volume of adipose tissue required to reconstruct
the breast mound post-mastectomy is more challenging [75]. According to the literature, autologous fat grafting
did not show promising success in breast reconstruction as expected with resorption rates ranging from 25 to
80% and complications [76]. These limitations consist of oil cyst formation, fat necrosis and calcifications for
example latissimus dorsi flap [76] or as a filler for small-volume defects post-breast cancer surgery [77,78]. In 2006,
for first time, Matsumoto et al. [79] tried to reduce the rate of resorption (cell-assisted lipo-transfer). This was done
through enrichment of autologous lipoaspirates with ADSCs prior to grafting. On the other hand, Kolle et al. [80]
showed that residual fat volume of >80% in ten patients enriched with ADSCs and compared with controls. The
outcome showed that there were higher amounts of adipose tissue, less necrotic tissue and newly formed connective
tissue in grafts enriched with ADSCs [81]. These studies are on-going from many researchers world-wide and there
is a huge interest as it has shown promising outcome so far.
Breast adipose tissue engineering (in vitro modeling of breast tissue)
For a better understanding of the breast tissue in terms of structure and function, cellular interactions in morpho-
genesis and carcinogenesis were evaluated using 2D models, yet revealing unsatisfactory reflection [18,82]. Actually,
crucial molecular signals required for tissue-specific architecture and function were lost in these models (i.e., failure
to trigger tissue-specific gene expression) [82].
Ultimately, this led to the development of 3D models, which provide a native-like microenvironment that
supports cellular attachment and migration and promotes cell–cell and cell–matrix interactions [83]. This enabled
the formation of structures that mimic the normal breast tissue [84], which subsequently participated in identifying
the essential biochemical and environmental signals for homeostasis and gene expression [82].
Mammary epithelial cells, within these constructs, form polarized organizations of the acinar and ductal struc-
tures, which reflects the stromal signals [23]. The significant research efforts of Bissell group resulted in the develop-
ment of 3D constructs using gel-based scaffolds, like Matrigel, collagen, Matrigel/collagen mix and laminin [18].
10.2217/rme-2020-0045 Regen. Med. (Epub ahead of print) future science group
Adipose tissue-derived mesenchymal stem cells for breast tissue regeneration Review
Table 6. A summary of followed approaches to tackle vascularization challenges, their actions and limitation.
Approach description Prospective action Limitations Ref.
Incorporation of endothelial cells or angiogenetic
factors within the tissue engineered construct or
delivering them to the site of the engineered
tissue
Combats hypoxia, promotes vascularization
through inducing blood vessels formation.
Failure of achieving a long-term sustained effect.
Raising concerns of oncological transformation in
post-cancerous cases while utilizing vascular
promoting factors.
[6,68]
Inducing foreign body reaction Enhances vascularization and vascular ingrowth
via eliciting host tissue response. Further
degradation of biomaterials may result in
by-products formation, maintaining that response
for defined intervals.
Temporary reaction that will reside after
termination of the response.
Insufficient for large tissue volume.
Slow process.
[69,70]
In vitro or in vivo, pre-vascularization of the
engineered tissue
Actively boosts vascularization process. Integration of the newly formed vessels with that
of the host is still challenging.
[6]
Microstamping using nanofluid chambers Supports cellular engraftment via establishing an
ex vivo 3D vascular bed in the long-term which
then anastomosed to the host vascular system.
An interesting approach applied in liver tissue
engineering but have not implemented for breast
tissue engineering yet.
[71]
Utilizing vascularized conduits Using a defined vascular pedicle to clinically
vascularize adipose tissue constructs.
Limited, no long-term data are yet available.
The potential ability of pre-existing vascular
pedicle to microsurgically transfer the engineered
construct to a remote site.
[7]
Mammary epithelial cells seeded into these constructs showed a low proliferation rate, formed polarized growth-
arrested structures and secreted BM [18].
Scaffolds for breast adipose tissue regeneration
Selecting the appropriate scaffold for breast tissue regeneration is a crucial factor to promote cell survival [18]. The
chemical composition and physical characteristics (microstructural and mechanical features) of the biomaterial
govern stem cells behavior and cell–scaffold interactions particularly cellular proliferation, differentiation and
adhesion [5,28,85], as this controls cellular responses via providing a biochemical and biophysical environment [5,86].
Moreover, patent microcirculation and ECM are inevitable prerequisites for the survival of the transplanted or
regenerated adipose tissue [87].
Ideal biomaterial-derived scaffolds used for breast tissue engineering should have specific features. Basically, the
physical, chemical and mechanical characteristics should resemble the normal breast tissue and enable 3D constructs
formation that can incorporate cells, growth factors and cellular adhesion functional groups [18]. It should induce
the formation of a native-like tissue (functionally and structurally) [5,28,60] and should have cellular affinity,
biocompatibility and special immunological properties to interact positively with cellular components [5,6,18]. In
addition to having in vivo end point, which means being biodegradable, to ensure the integration of the newly
formed tissue with the native tissue. Nevertheless, the degradation products should be nontoxic, metabolized and
removed from the body [6,18]. A salt-leaching method and a computer-controlled knife coater were utilized to
make regulated scaffolds, this was then assessed by seeding cells into the 3D scaffold and testing degradability [88].
This method showed that in PLGA and polyglycolic acid scaffolds, which pH levels decrease over time during
degradation, creating an acidic environment for the cells, thus affecting growth [88]. Whereas aliphatic polyesters
such as polycaprolactone (PCL), are more easily metabolized and do so via the Krebs cycle in a slow, more controlled
manner [88], therefore great consideration should be taken when choosing scaffold biomaterials. On the other hand,
balancing structural integrity with scaffold stiffness (flexibility) and constructive remodeling is the key to diminish
structural and functional deviation [5,28].
Unlike other tissue engineering applications, the breast, as previously mentioned, has a common chance of
developing cancer, making screening a recommended regular procedure, therefore it is vital that the chosen
biomaterial does not prohibit or hinder diagnostic imaging [30]. Compared with silicone implants, tissue engineered
scaffolds result in lower amounts of scar tissue, and they are also more porous and less radiopaque, thus interfering
less with imaging and once the scaffold has degraded interference should be eliminated entirely [30]. Furthermore, a
highly porous construct is essential to allow cellular ingrowth and differentiation, tissue integration, angiogenesis,
nutrients and wastes exchange and multipotent cells differentiation [6,28]. The most commonly investigated ECM
materials used as 3D culture scaffolds for breast tissue regeneration are Matrigel, collagen and its composites,
regenerated silk fibroin and polylactic acid [18] (Table 6).
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Sponge scaffolds
Rnjak-Kovacina et al. produced a variety of silk sponges, using an array of silk weight distributions, concentration
and crystallinity to achieve a scaffold with properties ideal for tissue engineering [89]. Silk sponges can be produced
by methods such as gas foaming, salt leaching and freeze-drying, the application of the sponge determining what
technique to carry out [90]. Freeze-drying is simply carried out by freezing a silk solution into a desired shape,
the freezing produces crystals which create the porous structure [91]. Freeze-drying can also be carried out using
porogens such as sodium chloride, however using just water to create the pores reduces solvent toxicity risks [91].
Rnjak-Kovacina et al. retrieved silk fibroin from Bombyx mori cocoons, removing the protein sericin to get pure
silk fibroin for different time periods (5, 10, 30 and 60 min), before placing the silk into lithium bromide to make
the silk soluble, at 60◦C with different times and with different lithium bromide concentrations [89]. Silk fibroin is
commonly used as a biomaterial due to its great mechanical properties, controllable degradation capabilities and
biocompatibility, giving properties useful to create implants [92]. After solubilizing the silk fibrins, the solution was
refined so that the bromine was removed, the concentration of the silk was determined at 6–8% wt/v and was
stored at 4◦C [89]. The solution was then either cast into molds or into wells and frozen at -20◦C overnight and
then freeze-dried at -80◦C for 48 h. The scaffolds were then demolded and annealed in water at different lengths
of time or autoclaved, before either using water or phosphate buffered saline to rehydrate the scaffolds [89].
These scaffolds had a variety of different properties due to the different times and molecular weight distributions,
but it was shown that scaffold cohesion was improved with increased silk molecular weight, polypeptide content
altering degradation rates and silk concentration controlled mechanical properties [89]. This method used human
MSCs (hMSCs) from bone marrow aspirate, however could be switched for ADSCs further to test if scaffold
properties would suit breast tissue engineering applications.
When deciding on what technique to use to produce a silk sponge scaffold, it should be considered that out of
the three mentioned techniques, the freeze-drying technique can have a porosity up to 99%, whereas salt leaching
and gas foamed have up to 98% and 97%, respectively [90]. If compressive strength is an important factor, gas
foamed scaffold is the strongest at around 175 KPa, as compared with salt leaching and freeze-drying which have
compressive strengths of around 280 and 30 KPa, respectively [90]. It is also notable, that silk fibroin can be used to
make hydrogels, fibers, microspheres and thin films to serve a range of applications [92].
Collagen can also be used to produce sponge scaffolds, although collagen is thought of to be one of the more
expensive biomaterials on the market, Lequeux et al. carried out an analysis of porcine autologous ADSCs seeded
onto a collagen scaffold [93]. These scaffolds were cultured for 10 days prior to subcutaneous implantation, into the
porcine and analyzed over a period [93]. This resulted in vascularized connective tissue with improved extracellular
matrix around the ADSCs, Lequeux et al. reporting that this combination of collagen scaffold with ADSCs served
as a good solution for repairing soft tissue, due to increasing the thickness of the skin, removing the problems
commonly associated with fat grafting [93]. Collagen sponges have been compared against esterified hyaluronic
acid and other sponge, these scaffolds were seeded and cultured in vitro with preadipocytes, then implanted into
nude mice [94]. Differentiation occurred the earliest in the hyaluronic scaffolds, showing more ECM than the other
two scaffold types and had a larger number of cells present than the other woven and nonwoven scaffolds [94].
Furthermore, showing that collagen and hyaluronic acid can be used as scaffolds, but produce different results, the
importance of choosing a suitable scaffold highlighted here as biomaterials can be modified to make large changes.
Hong et al. combined a gelatin sponge scaffold with human ADSCs, to analyze the differentiation and prolifer-
ation of these cells on a soft scaffold in vivo [12]. After implementing a medium to encourag0e adipogenicity, this
seeded scaffold was implanted into the backs of mice and within 4 weeks fat had formed from adipogenic cells [12].
This method and combination of gelatin scaffold with human ADSCs could be used to encourage fat growth,
using stem cells derived autologously to prevent immunological responses, with gelatin being an easily sourced
biomaterial as a scaffold choice.
Sponge scaffolds can create porous, soft and inexpensive constructs for ADSCs growth and differentiation,
potentially suitable for human breast reconstruction if caution and care is taken throughout the entire procedure.
Additive manufactured scaffolds
Lipofilling and tissue engineering can be combined together, creating a bespoke scaffold for each patient, allowing
cells to proliferate within the breast before lipofilling [30]. Where lipofilling has little to no mechanical strength and
structure of it cannot be controlled, a biodegrading scaffold would allow for a chosen shape and size supporting the
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growth of new cells. Chhaya et al. evaluated this combination of scaffold and lipofilling, by implanting an empty
scaffold, a scaffold containing lipoaspirate and an empty scaffold which had lipoaspirate injected, after a 2 week
prevascularization period, into minipigs [95]. Additive manufacturing was performed to create scaffolds from PCL,
but first liposuction had to take place in order to harvest lipoaspirate. Then these scaffolds were subglandularly
implanted into immunocompetent minipigs for 24 weeks [95]. The results from this experiment showed that
the combination of a scaffold with a delayed lipofilling, was the most successful histologically and has the most
similarities to natural breast tissue, containing approximately 47% of adipose tissue [95].
Bespoke patient scaffolds have been produced, by scanning the patients’ breast, then additive manufacturing was
carried out using polyD-L-lactide polymer as the biomaterial, in a process called fused deposition modeling [96].
Fused deposition modeling requires no solvents to be used alongside the aliphatic polyesters and has constant flow
as heating time is reduced, making the modeling easier to carry out compared with solid freeform fabrication or
3D printing [97].
Prior to seeding these scaffolds, human umbilical cord perivascular cells were cultured in vitro for 6 weeks,
human umbilical vein was also seeded into the scaffold, then this was then implanted subcutaneously into nude
rodents [96]. These bespoke-made polymer scaffolds after 24 weeks had an increase of adipose tissue in the area of
81.2%, tissue was also well vascularized, Chhaya et al. showing that these 3D additive manufactured methods are
suitable constructs for increasing adipose tissue within the breast [96].
Custom 3D scaffold production reduces surgery complexity, where a surgeon might have been required to shape
silicone implants to suit a patient or use a variety of tissue flaps together to produce a natively similar aesthetic
breast, additive manufacturing makes the procedure more straight forward [30], using scanning methods to copy
the desired shape accurately [96].
Gel scaffolds
An alternative to 3D structures for scaffolding, could be using gels such as hydrogels instead, which are polymeric
structures that swell when introduced to water [12,98]. These gels do not provide as much structural support or
mechanical strength, but can be injected into tissue and do not necessarily require surgery to implant. Wittmann
et al. demonstrated the usefulness of fibrin hydrogels, retrieving stromal-vascular fraction cells and combing these
with the hydrogels to form adipose tissue in vivo in nude mice [99]. These cells were cultured for 1 week prior to
in vivo implantation, after 4 weeks after histological and histomorphic evaluation, finding vascular structures and
mature adipocytes throughout the formed area [99].
Hydrogels can be produced from many polymers to allow soft tissue formation, a few examples include: PEG [100],
myogels [101], collagen [102] and hyaluronic acid [102].
Natural hydrogels may seem superior to synthetic hydrogels, because of their biodegradability and biocompat-
ibility capabilities, unfortunately despite that natural hydrogels commonly cause inflammatory reactions and are
not able to mechanical maintain the structure [98]. Synthetic hydrogels can be custom-made to improve strength,
biodegradability but there is still ongoing research on finding a way to synthetically represent the ECM and bioactive
molecules might need to be incorporated to encourage cell adhesion and migration [98].
PEG can be altered to slow or prevent degradation of the hydrogel, this can be done by introducing branches
or cross-linking of peptides and other structures [100]. Nondegrading hydrogels made from PEG have shown to be
less successful than enzymatically degradable hydrogels, in which enzymatically degradable hydrogels encourage
adipose-tissue like formation more thoroughly [100]. However, it should be noted that enzymatic degradation of
these degradable PEG hydrogels can occur in as little as within 10 days [100], which might not be long enough to
support the growing tissue structures.
To produce a hydrogel firstly, a combination of desired monomers needs to be collected with inhibitors, initiators
and cross-linking agents, this is then polymerized prior to preparing the hydrogel [103]. This is then separated and
washed, before drying and sizing [103]. Anything that is excess material can be repolymerized via recycling and used
again. After sizing additive inclusion can happen and post reaction may occur, once complete the hydrogel can
then be used or packaged appropriately [103]. It should be noted that this is only a vague overview of hydrogel
production, the timings, temperatures and quantities will vary depending on properties needed from the hydrogel.
Myogels have been used as scaffolds for adipose tissue support, as an alternative to matrigel scaffolds [101].
Myogels can be prepared from extracting extracellular matrices from skeletal muscle, made up of laminin and
collagen, Abberton et al. have shown this to be viable alternative, with similar discrepancies in growth factors to
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balance out their worth [101]. When used in vivo in rats, adipose tissue formed sufficiently along with vascularized
endothelium, an encouraging result to prevent cell necrosis [101].
Matrigel scaffolds alone have proved unsuccessful to meet the mechanical property requirements of the breast
ECM, yet in combination with collagen type one, the scaffolds have been shown to allow formation of ductal and
alveolar structures [104].
Microbeads can be used alongside hydrogels, microbeads can be used to increase porosity and allow morphological
control [103]. This can be done by using a phase including aqueous solution, cross-linking agents and monomers
with a dispersing agent and nonsolvent all combined [103]. Once stirred the initiator can be added to conduct
gelation of the mixture, and similar to the normal hydrogel process is separated and washed before drying, then the
hydrogel beads are formed [103].
Importantly, hydrogels have many flaws that could impede on the design of a tissue engineered scaffold for soft
tissue. Mimicking of the ECM is a critical component of a scaffold in ensuring cell survival, alongside controlling
the expansion of these hydrogels to limit molecular diffusion [98,105].
Electrospun scaffolds
Electrospinning is a commonly technique used for tissue engineering various scaffolds [106,107], however this is
usually in applications where cancer has not been an issue, as scaffold ECM could encourage the growth of
potentially malignant cells [108]. Electrospun scaffolds made from fibers can increase adipose tissue growth and
adhesion more so than collagen, while also being shown to act as an immunosuppressant, when using polymers
polydioxanone, polyglycolic acid, polylactic acid, and PCL [108,109].
Electrospinning has been used to model the shape, structure and environment of the breast in a 3D manner in
vitro, allowing a closely related environment to the native breast rather than using 2D structures [18]. 2D structures
having poorer cell proliferation and effective arrangement when compared with 3D structures, with the use of
ADSCs [110]. Nanofiber scaffolds can be produced to represent tissue fibers found in the breast ECM, encouraging
cell adhesion and biocompatibility, producing closely related 3D surroundings for scientists to test and explore how
breast cancer develops, this teaching how the cancer in the breast spreads working towards alternative treatments
or therapies [18].
Collagen fibers can sometimes proliferate and spread in the place of removed tissue during mastectomies, therefore
the texture and feel of this tissue can feel abnormal causing discomfort or looking unsightly to the patient [111].
Methods to increase adipose tissue in the place of collagen, becoming more important in the success of developing a
realistic tissue [111]. Where biopolymers, ECM structures and other native tissue structures need to be implemented
to provide the most natural tissue possible [108].
Electrospun scaffolds can be used to fill spaces, where the cancerous breast tissue has been removed from, as an
alternative to pedicled flap procedures [112], as previously mentioned fat transfer can result in tissue loose because of
necrosis. This has been shown to work better, increasing tissue area compared with fat transfer, allowing larger breast
volumes to be reconstructed, proving improvement with pore size increase to allow greater cell migration [112].
There are a multitude of ways electrospinning can be carried out, parameters can be altered where deemed
appropriate in order to obtain a scaffold with different properties.
In this experiment carried out by Sana et al., creating scaffolds with both aligned and nonaligned fibers, of
particular interest finding that radial alignment of collagen with tumors increased the invasion and metastasis of
tumors [108]. This method being shown to be useful for studying breast carcinoma development, which can be
modified to provide a 3D ECM model structure as closely similar to the native breast ECM as possible [108].
Scaffolds made via electrospinning can also be mixed with minced adipose tissues, slow-degrading scaffold
materials prevent the structure from failing as the cells proliferate and fill the site of the scaffold, with the inclusion
of endothelial cells being shown to advance adipose tissue proliferation [110]. Development of Electrospun scaffolds
still requires improvement, with these scaffolds having pores too small in size to allow sufficient cell seeding, larger
pore size resulting in poorer mechanical properties, hence potential for scaffolds produced from more than one
technique to eliminate disadvantages [109,113].
Clinical use in patients with breast cancer
As described above, ADSCs has great properties and advantages toward patients with breast cancer and aug-
mentation issues such as pro-survival, anti-apoptotic effects, pro-angiogenic [114], immunosuppression, immune-
modulatory [115], tissue growth, and cellular homing are dysregulated in tumor progression and metastasis [114,116].
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However, this is an important and fast-growing field and many researchers are very optimistic about the bright
future of breast tissue reconstruction using ADSCs.
Conclusion
Although, many breast reconstructive techniques have been utilized for post-mastectomy patients the goal of an
optimal stratification and achieving complication-free outcomes has not been reached yet. In light of that fact, breast
tissue engineering field employing ADSCs, in particular, has been scouted and this may open up great avenues
toward combating those obstacles in addition to paving the way for more desirable results in terms of patient
satisfaction and psychological improvement. However, further elucidations are needed to unveil many questioned
aspects in this realm like oncological safety for instance, and that necessitates well-structured randomized control
trials to accomplish the demanded ‘from benchside to bedside’ translation.
Future perspective
Few studies have been carried out on human patients involving breast tissue engineering, this is due to a range of
physiological reasons and risks involved, that could make a person’s life very uncomfortable or even increase the
chance of breast cancer reoccurring. Although many basic problems require addressing, such as volume of adipose
tissue, preventing malignancy growth within the tissue or reducing rejection rates before human trials increase,
breast tissue engineering can be improved a great deal more.
With breast development occurring most drastically through puberty and pregnancy [18], it is important to
consider that breast cancer could, although less commonly, appear at a young age in women. Women developing
breast cancer before having children, may still desire to have children one day if cancer is ridden of completely
and chances of reoccurrence are low, it is recommended that oncologists give advice on safety for the female, along
with waiting for a year for all radiation damage to have been removed from the body [117]. If a female does wish
to have a child, she may also wish to breast feed her child, this could be due to research showing that breast milk
can benefit growing children in ways such as development of organs, hair and nail growth, gut bacteria health and
reduced pathogen exposure [118]. This literature talks mainly about ADSCs for fat growth within the breast, but if
ducts and glands are required for the production of milk, other cells would need to be mixed specifically to allow
a mother to lactate, in response to pregnancy hormone stimulation [18]. This advancement would prove difficult
due to little understanding of the ECM signals involved in mammary gland acinus lactation [22]. Swamydas et al.
successfully have developed breast-like acini and ducts using a combination of Matrigel, collagen and agarose, in
3D culture environments [84]. Which with improvement could lead to a structure and architecture closely related
to the human native acini [84].
Nipple–areola complex reconstruction may also be required, to deliver the milk to the child. And even more
commonly, females might wish to preserve the areola for self-confidence purposes or otherwise. Reconstruction of
the nipple–areola complex could involve reattachment of the native nipple to vascular supplies, but some females
may lose their areolas due to cancer growth, therefore tissue engineering of the nipple–areola complex would also
be required [30].
However, safety may be again a factor here again as the child could be drinking milk from an unhealthy source,
which could adversely affect the child when they grow up. Some females, on the other hand, would not want to
breastfeed due to pain or other concerns they may have.
Chemotherapy is used in the treatment of cancer within the breast, despite this however, cancer can return to a
patient after remission. Therefore, other methods to prevent cancer returning, are highly sought after, to encourage
and to reassure the patient, rather than they fear having to go through the distress of cancer procedures again.
Antitumor biomaterials and drug delivery systems are growing more and more popular in cancer research.
Chemotherapy has many side effects and limitations, of which discourages some patients to carry out the
procedure as they fear the aftermath. Some side effects can include risk of infection or bleeding (from reduced
blood cells), hair loss, sickness and peripheral neuropathy [119], however there are many more adverse effects that are
undesirable. Nanoparticle drug delivery systems can be used to target cancer cells and act similarly to chemotherapy,
when drugs are held within these systems and coated with a material (such as PEG to allow distant travelling to target
cells), these drug-delivery-systems can be of benefit to a patient by using ligands to destroy malignant cells [120].
Fan et al. formed a drug-delivery-system that was able to target tumor cells, allowing drug release using
SiO2 AuNP-based nanoparticles at the target site experimenting in vivo, reducing the tumor size to 0.0025%
of its original size, decreasing systemic toxicity and acting as an antitumor [120]. These systems can be improved
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and tested in environments more closely related to native breast tissue rather than in vivo, to give a clearer result
of the safety and implications there may be of using these drug systems in a human body within different sorts of
cells [120].
Due to the adaptability of electrospinning techniques, to produce scaffolds for tissue engineering, not only can
these electrospun scaffolds be used for tissue growth directing and acting as local ECM, but they can also be
used to deliver drugs to specific locations in the body [121]. This could be utilized to directly disperse a cancer
therapy drug at a required location, where the addition of drugs to the scaffold can be done simply, the large
surface area involved improving drug release control [121]. However, although processes similar to drug delivery and
encapsulation have been trialed using coaxial electrospinning with a variety of polymers [122,123] there are still many
problems concerning effective drug delivery. Drug release can be premature [121] therefore not reaching the target
site, however hydrophobic polymers are being explored as a solution to this, alongside the angle of the fibers to
control the release more strictly [113]. Alongside this issue, the drug itself must not be affected during production of
the delivery structure, as conditions such as temperature or voltage, may alter the effectivity or performance of the
drug [121]. Thus, research has been going into fiber production which affects the drug minimally, as such studies as
demonstrated by Mickova et al., showing how coaxial electrospinning allows enzymes to be held inside of polymer
PVA core with PCL shell to be obtained, holding back early enzymatic activation [122]. Hence, techniques like these
can be carried forward to slow drug release through the carrier structure where required. Also, when the content of
drug within the structures is increased, it has been seen to worsen the mechanical properties [124]. Throughout, the
major benefit of targeted drug delivery through tissue engineered scaffolds, hoping to minimize the area effected
by the drug and hence reducing the side effects of procedures such as chemotherapy.
Another method to reduce mortality associated with the reoccurrence potential of breast cancer, could involve
malignant growth detection via chemicals within the scaffolds. Research has been growing in the area of exploring
how MSCs home from afar and travel towards breast tumors, using this to trigger a warning preventing hidden
growth of malignant cells [125]. This is due to tumor cell-specific receptors present on surfaces, tumor-derived factors
and many other influences from MSCs [125]. In vivo studies by Khakoo et al., have shown that human MSCs can
be used to slow or stop tumor growth of Kaposi’s sarcoma as well as homing to malignant areas [126]. MSCs can
be administered to the body through intravenous drips, however this can get stuck where not required so not all
reach the target site [125], therefore a method of releasing the MSCs slowly from the scaffold, perhaps at the same
time as degradation would be beneficial in allowing the MSCs to quickly reach the homed tissue. These MSCs
can be tracked to find potential tumor activity using methods such as magnetic resonance imaging or computed
tomography, with various advantages and disadvantages associated with these methods [125].
Scaling up scaffolds for tissue engineering breast for reconstruction, is another problem, with current methods
focusing on very small production batches. A method to industrialize and mass produce tissue engineered breast
tissue, for the bespoke requirement of the patients may be complicated, but a line production technique may
be necessary in order to keep up with the quantities of people needing breast reconstruction involving tissue
engineering processes.
Few future directions of breast tissue engineering have been discussed here, with many more possible upgrades
to these processes and outcomes for patients, but with continued research and study these visions will become true.
Overall, the future of breast tissue engineering can advance immensely, and once the breast is understood completely
at a cellular level and can be replicated closely, the repercussions of breast surgery can be near to eradicated. In turn,
improving the lives of breast cancer patients.
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Executive summary
Breast anatomy, histology & development
• Breast anatomy, histology and development discussed.
Epithelial cells interactions with extracellular matrix proteins
• Epithelial cells survival, proliferation, differentiation, polarity and invasive capacity are governed by cell–cell and
cell–microenvironment interactions.
Biomechanical properties of breast tissue
• The mechanical properties of the soft tissues involve a sophisticated combination of elasticity and viscosity that
governs tissue deformation.
Current clinical practices for breast reconstruction
• There are two factors determining the type and timing of the reconstructive procedure, patient’s general health
status and then patient’s preference.
• Implant-based reconstruction: associated with several complications that may lead to implant failure.
• Autologous flap reconstruction: more complex with longer recovery and are associated with potential donor and
recipient-site morbidity.
Challenges facing adipose tissue engineering for breast regeneration
• Breast adipose tissue engineering: enabled the formation of structures that mimic the normal breast tissue.
• Scaffolds for breast adipose tissue regeneration: The most commonly investigated extracellular matrix materials
used as 3D culture scaffolds for breast tissue regeneration are Matrigel, collagen and its composites, regenerated
silk fibroin and polylactic acid.
Scaffolds for scaffolds for breast tissue regeneration
• Additive manufactured scaffolds: additive manufacturing was performed to create scaffolds from
polycaprolactone, but firstly liposuction had to take place in order to harvest lipoaspirate.
• Gel scaffolds: an alternative to 3D structures for scaffolding, could be using gels such as hydrogels instead, which
are polymeric structures that swell when introduced to water.
• Electrospun scaffolds: electrospun scaffolds made from fibers can increase adipose tissue growth and adhesion
more so than collagen, while also being shown to act as an immunosuppressant.
Adipose tissue-derived stem cells
• Adipose tissue-derived stem cells (ADSCs): ADSCs prevent severe graft-versus-host disease in vitro and in vivo and
to be genetically stable in long-term culture and therefore they have great potential applications for the repair
and regeneration of acutely and chronically-damaged tissues.
• Cell survival and vascularization: ensuring adequate nutrition and oxygenation have been recognized as a critical
challenge in tissue engineering field in general and breast tissue engineering.
• Volume-skin coverage coordination: utilizing tissue engineering modalities allow an opportunity of
predetermining the desired shape and size of the restored breast by determining the scaffold shape and cell
numbers.
Application of ADSCs in tissue engineering
• ADSCs used as an important cell source and also known as the gold standard for many applications in
regenerative medicine.
Clinical use in patients with breast cancer
• ADSCs has great properties and advantages toward patients with breast cancer and augmentation issues such as
pro-survival, anti-apoptotic effects, pro-angiogenic, immunosuppression, immune-modulatory, tissue growth and
cellular homing are dysregulated in tumor progression and metastasis.
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